Holen Sie sich die Stockscreener-App
85.75
2.69%
-2.37
Handel nachbörslich:
85.00
-0.75
-0.87%
Schlusskurs vom Vortag:
$88.12
Offen:
$87.18
24-Stunden-Volumen:
1.12M
Relative Volume:
0.66
Marktkapitalisierung:
$5.39B
Einnahmen:
Nettoeinkommen (Verlust:
$-230.66M
KGV:
-20.54
EPS:
-4.1742
Netto-Cashflow:
$-148.12M
1W Leistung:
-14.14%
1M Leistung:
+161.67%
6M Leistung:
+112.20%
1J Leistung:
+474.73%
1-Tages-Spanne:
$85.20
$89.78
1-Wochen-Bereich:
$79.06
$103.27
52-Wochen-Spanne:
$13.95
$104.00
Kodiak Sciences Inc Stock (KOD) Company Profile
Firmenname
Kodiak Sciences Inc
Sektor
Branche
Telefon
650-281-0850
Adresse
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
85.75 | 5.39B | 0 | -230.66M | -148.12M | -4.1742 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-24 | Fortgesetzt | Goldman | Neutral |
| 2026-05-11 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2025-11-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-25 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2025-09-22 | Eingeleitet | Jefferies | Buy |
| 2025-08-14 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-09-05 | Eingeleitet | H.C. Wainwright | Neutral |
| 2023-12-11 | Fortgesetzt | Goldman | Sell |
| 2023-11-17 | Hochstufung | CapitalOne | Equal Weight → Overweight |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-25 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2023-07-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-07-24 | Herabstufung | CapitalOne | Overweight → Equal Weight |
| 2023-07-24 | Herabstufung | Jefferies | Buy → Hold |
| 2022-11-15 | Eingeleitet | CapitalOne | Overweight |
| 2022-08-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-02-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2022-02-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-02-17 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-01-25 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-12-11 | Eingeleitet | Citigroup | Neutral |
| 2020-11-30 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-11-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-03 | Eingeleitet | Goldman | Buy |
| 2020-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-02-06 | Eingeleitet | SunTrust | Buy |
| 2020-01-08 | Eingeleitet | ROTH Capital | Buy |
| 2020-01-03 | Eingeleitet | Jefferies | Buy |
| 2019-12-24 | Eingeleitet | JP Morgan | Overweight |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2018-10-29 | Eingeleitet | Barclays | Overweight |
| 2018-10-29 | Eingeleitet | BofA/Merrill | Buy |
| 2018-10-29 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Kodiak Sciences Inc Aktie (KOD) Neueste Nachrichten
Kodiak Sciences Inc. (KOD) stock price, news, quote and history - Yahoo Finance Singapore
Kodiak Sciences More Than Doubles on Eye Disease Trial Results - Barchart.com
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com South Africa
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Nigeria
Form 13D/A Kodiak Sciences Inc. For: 1 October By Investing.com - Investing.com Canada
Kodiak Sciences(KOD.US) 10% Shareholder Buys US$156.99 Million in Common Stock - Moomoo
A stock acquisition changes beneficial ownership by more than 1% at Kodiak Sciences (KOD). - Stock Titan
Baker Bros. Advisors Reports Multiple Open-Market Buys of Kodiak Sciences Stock - Kalkine Media
In 30 transactions, Baker funds bought shares of Kodiak Sciences (KOD). - Stock Titan
Funds buy Kodiak Sciences (KOD) shares at average prices of about $79–$86. - Stock Titan
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Canada
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com South Africa
Form 4 Kodiak Sciences Inc For: 29 September By Investing.com - Investing.com Nigeria
Options at $2.49 a share are among those Kodiak Sciences (KOD) CEO exercised. - Stock Titan
Diluted net income available to common stockholders of Kodiak Sciences, Inc. – HAN:K27 - TradingView
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears - Zacks Investment Research
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs? - Stocktwits
Kodiak Sciences Inc (NASDAQ: KOD) Share Price, KOD Stock News, KOD Share Price & Updates - Kalkine
Form 8K Kodiak Sciences Inc For: 28 September By Investing.com - Investing.com Canada
Form 8K Kodiak Sciences Inc For: 28 September By Investing.com - Investing.com India
Both treatments met a year-one vision goal in Kodiak Sciences (KOD)'s eye disease trial. - Stock Titan
Why Is Kodiak Sciences (NASDAQ:KOD) Suddenly a Must-Watch Healthcare Stocks Name? - Kalkine Media
Kodiak Sciences (Nasdaq:KOD)Stock Analysis - Simply Wall Street
Kodiak Stock Soars (Again) As Data Shows Long-Lasting Eye Meds Are The 'Real Deal' (KOD) - Seeking Alpha
Kodiak Sciences to report phase 3 trial results Monday By Investing.com - Investing.com South Africa
What DAYBREAK Trial Results Could Mean For Kodiak Sciences Stock - simplywall.st
Goldman Sachs initiates Kodiak Sciences stock coverage with neutral rating - Investing.com
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte - Zacks Investment Research
Kodiak Sciences (KOD) Pulls Back After A Strong Year, Is The Valuation Still Too Rich? - simplywall.st
H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Kodiak Sciences stock rating on trial outlook - Investing.com India
After $435,870 sale, Gilead (NASDAQ: GILD) CFO still holds 164K shares - Stock Titan
3 Small-Cap Biotechs With Binary Catalysts on the Calendar - marketbeat.com
Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts - Yahoo Finance
Kodiak Sciences (KOD): Three Phase 3 Readouts In SightWill The Data See It Through? - RTTNews
Former Sight Sciences (NASDAQ: SGHT) officer lines up more share sales after a string of summer trades - Stock Titan
Kodiak Sciences Inc (KOD) Peer Comparison – Compare with Others - valueresearchonline.com
What Kodiak Sciences (KOD)'s Widening Net Losses and Lower H1 Loss Per Share Mean For Shareholders - simplywall.st
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants - Yahoo Finance
Kodiak Sciences (NASDAQ:KOD) Stock Price Down 4.1%Time to Sell? - MarketBeat
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com - Investing.com Nigeria
HC Wainwright Lowers Earnings Estimates for Kodiak Sciences - MarketBeat
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD - MarketBeat
KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58 - GuruFocus
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com Nigeria
HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD) - MarketBeat
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy - Investing.com
Finanzdaten der Kodiak Sciences Inc-Aktie (KOD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Kodiak Sciences Inc-Aktie (KOD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director |
Sep 29 '26 |
Buy |
85.05 |
33,726 |
2,868,255 |
20,191,214 |
| BAKER BROS. ADVISORS LP | Director |
Sep 28 '26 |
Buy |
83.58 |
418,323 |
34,963,077 |
19,515,907 |
| BAKER BROS. ADVISORS LP | Director |
Sep 28 '26 |
Buy |
72.57 |
807,840 |
58,625,708 |
19,121,134 |
| PERLROTH VICTOR | Chairman and CEO |
Sep 25 '26 |
Option Exercise |
4.20 |
1,280,524 |
5,381,943 |
3,676,062 |
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Sale |
34.10 |
30,000 |
1,023,009 |
211,930 |
| JOHN BORGESON | Officer |
Jun 04 '26 |
Proposed Sale |
33.87 |
30,000 |
1,016,100 |
0 |
| BORGESON JOHN A. | Chief Financial Officer |
Jun 04 '26 |
Option Exercise |
1.04 |
30,000 |
31,200 |
241,930 |
| BORGESON JOHN A. | Chief Financial Officer |
Apr 15 '26 |
Option Exercise |
1.04 |
28,614 |
29,759 |
211,930 |
| JOHN BORGESON | Officer |
Apr 02 '26 |
Proposed Sale |
42.81 |
30,000 |
1,284,300 |
0 |
| BORGESON JOHN A. | Chief Financial Officer |
Apr 02 '26 |
Sale |
39.92 |
30,000 |
1,197,488 |
183,316 |
3.25%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):